April 2, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549-3720
| Attention: | Daniel Crawford | |
| Laura Crotty | ||
| Ibolya Ignat | ||
| Kevin Juhar |
| Re: | Contineum Therapeutics, Inc. |
Amendment No. 1 to Registration Statement on Form S-1
Filed April 1, 2024
File No. 333-278003
CIK No: 0001855175
Request for Acceleration of Effective Date
Requested Date: Thursday, April 4, 2024
Requested Time: 4:00 P.M. Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 460 under the Securities Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the public offering of shares of the Registrant’s Class A common stock, as many copies of the preliminary prospectus of Contineum Therapeutics, Inc. (the “Registrant”) as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned Representatives, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering.
In accordance with Rule 461 of the Securities Act, we hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on April 4, 2024, or such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. We, the undersigned Representatives, confirm that the underwriters are aware of their obligations under the Securities Act.
[Signature Page Follows]
| Very truly yours, | ||
| GOLDMAN SACHS & CO. LLC | ||
| MORGAN STANLEY & CO. LLC | ||
| As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement | ||
| GOLDMAN SACHS & CO. LLC | ||
| By: | /s/ Lyla Bibi Maduri | |
| Name: | Lyla Bibi Maduri | |
| Title: | Managing Director | |
| MORGAN STANLEY & CO. LLC | ||
| By: | /s/ Chirag D. Surti | |
| Name: | Chirag D. Surti | |
| Title: | Executive Director | |
| cc: | Carmine Stengone, Chief Executive Officer and President, Contineum Therapeutics, Inc. |
Jeffrey Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Ryan J. Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Leanne A. Gould, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
Frank F. Rahmani, Sidley Austin LLP
Samir A. Gandhi, Sidley Austin LLP
J. Carlton Fleming, Sidley Austin LLP
Kostian Ciko, Sidley Austin LLP
[Signature Page to Underwriter Acceleration Request]